Oral Wegovy vs Injectable Wegovy: How They Compare

As of December 22, 2025, Wegovy is available in two forms: the original once-weekly subcutaneous injection (semaglutide 2.4 mg) and a newer once-daily oral tablet (semaglutide 25 mg). Both are FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, and both are approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. The active ingredient is the same, but the two forms differ in how you take them, the magnitude of weight loss in trials, cost and access, and some practical tradeoffs.

What's the Same

Both forms of Wegovy contain semaglutide, a GLP-1 receptor agonist. Both are approved for:

• Chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbid condition
• Reduction of the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight

Both are taken as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone treatment. Both carry the GLP-1 class boxed warning regarding thyroid C-cell tumors and share the same contraindications (personal or family history of medullary thyroid carcinoma, MEN 2, and known hypersensitivity to semaglutide).

How You Take Them

This is the most obvious difference.

Injectable Wegovy: Once-weekly subcutaneous injection using a prefilled pen. You rotate between your abdomen, thigh, or upper arm. The pen does not require refrigeration once you're using it (though unopened pens are refrigerated). Dosing escalates over approximately 16-20 weeks from 0.25 mg to the target 2.4 mg weekly dose.

Oral Wegovy: Once-daily tablet taken on an empty stomach. You swallow it with up to 4 ounces of plain water, at least 30 minutes before the first food, beverage, or other oral medications of the day. Tablets are supplied in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths. Dosing escalates over several months to the 25 mg target dose.

The oral pill format removes the injection barrier for patients who are needle-averse. The tradeoff is the daily morning ritual: you must take the tablet first thing on an empty stomach and wait 30 minutes before eating, drinking anything except a small amount of water, or taking other medications. Patients used to morning coffee or medication routines will need to rethink their morning.

Weight Loss: Clinical Trial Data

Each form of Wegovy has its own pivotal trial. Direct head-to-head data between oral and injectable Wegovy is limited at the time of approval, so results must be compared across different studies with different designs.

OASIS 4 (oral Wegovy 25 mg, 64 weeks):

• With full treatment adherence, oral semaglutide 25 mg produced approximately 16.6% mean body weight reduction versus about 2.7% with placebo
• About 34.4% of adherent participants achieved at least 20% weight loss (vs 2.9% on placebo)

STEP 1 (injectable Wegovy 2.4 mg, 68 weeks):

• Injectable semaglutide 2.4 mg produced approximately 14.9% mean body weight reduction versus about 2.4% with placebo
• About 86% of participants achieved at least 5% weight loss and roughly 32% achieved at least 20%

Under adherent-treatment analyses, oral Wegovy's efficacy appears comparable to (and in some metrics numerically higher than) injectable Wegovy. In real-world use, adherence to a daily fasted oral regimen may be more variable than adherence to a weekly injection, which can affect actual outcomes.

Cardiovascular Evidence

Injectable Wegovy has specific cardiovascular outcome data from the SELECT trial, which demonstrated a significant reduction in major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. This trial supports the cardiovascular indication on the injectable Wegovy label.

Oral Wegovy's cardiovascular indication was granted based on the established cardiovascular benefit of semaglutide as a molecule, extended to the oral 25 mg formulation. Ongoing studies will further characterize long-term outcomes specifically for the oral form.

Side Effects

Both forms share the GLP-1 class side-effect pattern: predominantly gastrointestinal (nausea, vomiting, diarrhea, constipation, abdominal pain). Most side effects are mild to moderate and improve with slow dose titration.

Injectable Wegovy: May additionally cause injection-site reactions (redness, itching, or bruising at the injection site).

Oral Wegovy: No injection-site reactions, but the fasted administration requirement means some patients report more variable GI tolerability depending on how strictly they follow the 30-minute water-only window. Taking the tablet with food or insufficient water can reduce absorption and effect.

Both forms carry the boxed warning regarding thyroid C-cell tumors and the same contraindications. Both may increase risks of pancreatitis, gallbladder disease, and acute kidney injury in the context of dehydration from GI side effects.

Cost and Access

Cost is one of the biggest practical differences at launch.

Injectable Wegovy: List price roughly $1,349-$1,650 per month. Many commercial plans exclude weight-loss medications from coverage, though coverage has expanded in plans where the patient has cardiovascular disease. Savings card programs can reduce out-of-pocket cost for eligible commercially insured patients.

Oral Wegovy: Novo Nordisk has launched oral Wegovy at approximately $149 per month without insurance through direct-pay channels, significantly reducing the self-pay barrier. Insurance formulary treatment of oral Wegovy is still evolving in early 2026, so patients should confirm with their plan.

This pricing gap is unusually large for same-molecule, same-brand medications and reflects Novo Nordisk's strategy to increase oral access for patients who cannot afford injectable Wegovy or whose plans do not cover it.

Which Form Fits Which Patient

• A patient who prefers to avoid needles and is willing to follow a daily fasted routine may prefer the oral pill.
• A patient who prefers less-frequent dosing and does not want to organize their morning around a 30-minute fasted window may prefer the weekly injection.
• A patient paying out of pocket may find oral Wegovy's approximate $149 monthly price significantly more accessible than injectable Wegovy's self-pay cost.
• A patient with established cardiovascular disease and obesity or overweight may consider the injectable form first, given the well-characterized cardiovascular outcome data from SELECT, though the oral form shares the cardiovascular indication.
• A patient who has failed injectable Wegovy due to tolerability or adherence may discuss oral Wegovy with their provider as an alternative within the same molecule.

For a broader overview of oral versus injectable GLP-1 options across all medications, see our oral vs injectable GLP-1 guide. For comparisons with other oral GLP-1 options for weight loss, see Foundayo (orforglipron) vs Wegovy.

When to Talk to Your Doctor

If you are considering switching between forms of Wegovy, or starting either one for the first time, discuss with your prescriber your overall health, cardiovascular risk, insurance coverage, daily routine, and any history of GI issues or thyroid disease. Switching between forms of the same molecule is generally straightforward from a pharmacologic standpoint but can be affected by dose equivalence, titration timing, and insurance authorization.

This article is for informational purposes only and does not constitute medical advice. Prescribing decisions should be made between a patient and their healthcare provider based on the most current FDA labels and the patient's individual health profile.